Boston Scientific’s Improving ICD Sales Offset Slow Stent Revenues In Q1
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's recent resolution of a warning letter pertaining to quality control deficiencies at one of its cardiac rhythm management device manufacturing plants should help increase sales of the implants in the coming quarters, the firm says